Fulcrum Therapeutics, Inc.
FULCHealthcare|Biotechnology|US
$3.70
+0.02 (+0.54%)
DCF Value
$3.01
Tangible Book / Share
$4.07
Cash / Share
$4.18
Clinical Trials (11)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04511819 Losmapimod Safety and Efficacy in COVID-19 | COVID-19 | P3 | Terminated | 52 | RCT, Double-blind | Losmapimod oral tablet, Placebo oral tablet |
| NCT05397470 Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH) | Facioscapulohumeral Muscular Dystrophy (FSHD) | P3 | Terminated | 260 | RCT, Double-blind | Losmapimod, Placebo oral tablet |
| NCT04003974 Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) | Facioscapulohumeral Muscular Dystrophy (FSHD) | P2 | Completed | 80 | RCT, Double-blind | Losmapimod oral tablet, Placebo oral tablet |
| NCT00859716 ACE393-103 Vaccination Challenge Study | Campylobacter Infection | P2 | Unknown | 72 | RCT, Double-blind | ACE393, Placebo vaccine |
| NCT04264442 Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE) | Facioscapulohumeral Muscular Dystrophy (FSHD) | P2 | Terminated | 76 | Open-label | Losmapimod |
| NCT04004000 Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension | Facioscapulohumeral Muscular Dystrophy 1 | P2 | Terminated | 14 | Open-label | Losmapimod |
| NCT07401823 Open-Label Extension Study to Pioneer Study 6058-SCD-101 | Sickle Cell Disease | P2 | Terminated | 1 | Open-label | Pociredir |
| NCT05002231 Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets | Healthy Adult Subjects | P1 | Completed | 18 | RCT, Double-blind | Losmapimod 15 mg oral tablet, Losmapimod two 7.5 mg oral tablets, Losmapimod one 15 mg oral tablet |
| NCT07431398 Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease | Sickle Cell Disease | P1 | Terminated | 13 | Open-label | Pociredir |
| NCT04586985 Safety, Tolerability and Pharmacokinetics of FTX-6058 | Healthy Adult Subjects, Sickle Cell Disease | P1 | Completed | 109 | RCT, Double-blind | FTX-6058/placebo oral capsule(s), FTX-6058/placebo oral capsule(s), FTX-6058 - Two Dosing Periods, FTX-6058 / Midazolam Syrup, FTX-6058/placebo oral capsule(s) |
| NCT05169580 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir | Sickle Cell Disease, Sickle Cell Anemia | P1 | Completed | 45 | Open-label | Pociredir oral capsule(s) |